Title: Prescription Birth Control Tydemy Recalled by Lupin Pharmaceuticals Over Potency Concerns
Date: [Insert Date]
The Food and Drug Administration (FDA) has issued a recall for two batches of the prescription birth control Tydemy. Lupin Pharmaceuticals, the manufacturer, initiated the voluntary recall after concerns were raised about reduced potency. The FDA’s testing revealed that the pills contained decreased levels of the inactive ingredient ascorbic acid and high levels of a “known impurity.”
Despite these findings, the FDA has stated that it has not received any reports of adverse events related to Tydemy. However, as a precautionary measure, patients are advised to continue taking Tydemy but should immediately contact their pharmacist, physician, or medical provider for advice.
The two recalled lots, labeled as L200183 and L201560, were distributed from June 3, 2022, to May 31, 2023, and have expiration dates of either January or September 2024. Patients who have obtained Tydemy from these lots are urged to return them to Inmar Rx Solutions for reimbursement.
To address any concerns or inquiries regarding the recall, consumers, wholesalers, distributors, and retailers can contact Inmar Rx Solutions directly at (866) 480-8206.
In response to this recall, The Post reached out to Lupin Pharmaceuticals for comment. As of now, the company has not provided a response. Matzav Blog will continue to monitor this situation and update readers with any further developments.
It is important for those affected by this recall to stay informed and take appropriate action. The FDA’s prompt response and the voluntary recall by Lupin Pharmaceuticals demonstrate a commitment to ensuring the safety and well-being of patients.
“Prone to fits of apathy. Devoted music geek. Troublemaker. Typical analyst. Alcohol practitioner. Food junkie. Passionate tv fan. Web expert.”